Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Oncology Exam 2 > Growth Factors > Flashcards

Growth Factors Flashcards

1
Q

Anemia is treated with

A

ESA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Neutropenia is treated with

A

CSF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mucositis/stomatitis is treated with

A

Kerotinocyte GF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Two Lineages of Blood Stem Cells

A

Myeloid

Lymphoid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Myeloid makes

A

erythrocytes, platelets, monocytes, basophils, eosinophils and neutrophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Lymphoid makes

A

Lymphocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Decreased oxygen delivery to kidney leads to

A

→ erythropoietin is generated by the kidneys due to sensing a low O2 level → increased oxygen delivery to tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Male Anemia

A

Less than 14

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Female Anemia

A

Less than 12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Side effects of anemia

A

headache, dizziness, malabsorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Moderate Anemia =

A

8-10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Severe Anemia =

A

6.5-7.9

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the Cancer-Related Causes of Anemia

A 
o	Chemotherapy/radiation therapy
o	Anemia of chronic disease (leukemias, lymphomas, ovarian cancers)
o	Blood loss
o	Bone marrow infiltration
o	Nutritional deficiency
o	Hemolysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Common cancers that cause Anemia

A

o Gynecological cancers, lymphoma/myeloma, and leukemi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Predisposing Factors for Anemia

A

Chemotherapy
Radiation
Combodities (renal, cancers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Chemotherapeutic Agents that CAUSE anemia

A

Low grade: 5FU, taxels, CHOP, taxel + anthracycline

High: Toptecan, cisplatin, Ciplatin + etoposide, VIP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Benefits and Risk of RBC transfusions

A 
o	Graft-Versus-Host-Disease
o	Transfusion Related Acute Lung Injury
o	Allergy/anaphylaxis
o	Infections (HIV, HBV, HCV, HTLV, etc)
o	1 Unit of RBC → 1 g/dL increase in 1 hour
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

ESA main purpose

A

Decrease the need for transfusions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

ESA Drugs and Dosing

A

Epoetin alfa: 3 times a week

Barbepoeitin alfa: SC Qweekly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

ESA AE

A

 Fever, dehydration, vomiting, pneumonia, fatigue, THROMBOTIC EVENTS

21
Q

ESA Caution

A

OVERALL INCREASE IN THROMBOVASCUALR EVENTS AND DECREASE SURVIVAL RATE

22
Q

Why decreased overall survival rate with ESA

A

 When you give EPO to cure anemia, you may be indirectly stimulating proliferation of cancer cells SO NEVER give EPO when you have a curable cancer because it increases tumor oxidation and growth

23
Q

***WHEN TO USE ESA?

A

 Chronic kidney disease, ESRD due to T2 DM
 Non-myeloid and non-erythoid cancers
 HIV-Induced
 Patients undergoing hip or knee replacement surgery
 Stem cell transplantation and immunosuppressed patients
 Patients treated with chemotherapy and an Hgb level of

24
Q

WHEN TO NOT USE ESA?

A

 Curable cancers
 Cancer-induced anemia
 Hematological cancers (leukemia, lymphomas)

25
Q

Neutropenia + Chemo

A

Most common dose-limiting toxicity

Between 7-14 days with recovery by day 21-28

26
Q

Consequences of Neutropenia

A

Increased risk of infection, use of abx, and hospitalization
Compromises treatment efficacy
QofL impact

27
Q

Prevention of Neutropenia

A

Dose reduction or delay

G-CSF or GM-CSF hematopoietic growth factors

28
Q

What is G-CSF?

A

 Glycoprotein + growth factor + cytokine
 Presents on precursor cells in bone marrow where it initiates proliferation and differentiation into mature granulocytes to stimulate bone marrow cell release into circulation

29
Q

Filgramstim MOA and Dose

A

• Regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation, differentiation and functional activation
Dose: daily for 4-14 days and last for 24 hours

30
Q

Pegfilgramstim MOA and Dose

A

Pegylated form of filgramstim

Dose: one dose Q2weeks

31
Q

Sacramostim MOA and Use

A

• Stimulates myelopoiesis generally and neutrophils and monocytes specifically
Used after BM transplan

32
Q

Use of CSF

A

 Post chemotherapy febrile neutropenia
 When the risk of febrile neutropenia is 20% and no other equally effective regimen is available
 Potent inducer of hematopoietic stem cell mobilization for stem cell transplant
 Severe chronic neutropenia
 Prevention of FN
 Peripheral stem cell mobilzation
 Accelerate recovery of neutrophils following stem cell transplantation

33
Q

CSF Dosing

A

Always give 24 hours after starting chemotherapy

34
Q

AE of CSF

A

 Common: bone pain, elevated uric acid, arthralgia/myalgia

 Serious: splenic rupture, sickle cell crsis, anaphylaxis, respiratory distress

35
Q

Clinical Pearls of CSF

A

 Begin at least 24 hrs after last dose of chemotherapy
 No change in infection-related or overall mortality with treatment
 Use for prevention of febrile neutropenia is better than treatment
 Higher costs is an issue.

36
Q

Define Mucositis

A

Inflammation of the mucosal surfaces through the body (esophagus, duodenum, colon, stomach, intestines, rectum)

37
Q

Mucositis Mechanisms

A

 Characterized by damage to the epithelium of the oropharyngeal cavity and GI tract
 Release of cytokines and growth factors → Inflammation → Tissue damage → Ulceration of mucosa

38
Q

Mucositis Symptoms

A

 Pain
 Difficulty eating/talking
 Abdominal pain
 Diarrhea

39
Q

Complications

A

 Impaired QofL
 Decreased activity
 Bacteremia/sepsis
 Poor nutrition

40
Q

Grade 1 Mucositis

A

Painless ulcers, erthema or mild soreness in the absence of lesions

41
Q

Grade 2 Mucositis

A

Painful erythema, edema or ulcers but eating or swallowing possible

42
Q

Grade 3 Mucositis

A

Painful erythema, edema, or ulcers requiring IV hydration

43
Q

Grade 4 Mucositis

A

Severe ulceration or requiring parenteral or enteral nutritional support or prophylactic intubation

44
Q

Phases Of Skin After giving Keratinocyte Growth Factor

A

o Phase 1: initiation: Reduce DNA damage; Increase levels of detoxifing enzymes to protect against ROS
o Phase 2: Signaling: Decrease levels of pro-inflammatory cytokines; Decrease apoptosis
o Phase 3: Amplification : Continuation of Phase 1 and 2
o Phase 4: Ulceration: As a result: reduced ulceration and pain
o Phase 5: healing

45
Q

Keratinocyte Growth Factor Drug

A

Kepivance

46
Q

Kepivance MOA

A

Induces cell proliferation, increases epithelial thickness and upregulates cytoprotective mechanisms

47
Q

Kepivance Indications

A

Hematologic cancers, high dose chemo + total body irradiation, stem cell transplant

48
Q

Kepivance AE

A

o Skin erythema
o Fatigue
o Tongue “feeling thick” or discoloration
o Taste disturbances

Oncology Exam 2 (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions